MarketCapExport financials
Sensei Biotherapeutics (SNSE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sensei Biotherapeutics Balance Sheet 2025-2011 | SNSE
Brief overview of Sensei Biotherapeutics's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Across five reporting periods, assets decreased -85.1%, from $153.2 million to $22.9 million, producing a negative trend.
Funding shifted toward liabilities: they gained -35.8%, compared with -85.1% for assets.
Internal capital represents 81.2% of the balance sheet, previously 95.6%. This is a strong capital position.
Cash accounts for 37.8% of assets versus 4.7% initially. The change indicates the degree of financial flexibility.
Retained earnings are negative at -$283.1 million. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Overall picture
Sensei Biotherapeutics's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Sensei Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -8.31 M | -10.7 M | -15 M | -5.48 M | -15.5 M | 15.8 M | 4.09 M | - | - | - | - | - | - | - |
Long Term Debt |
- | 98 K | 768 K | 1.58 M | 1.67 M | 567 K | - | 4.05 M | - | - | - | - | - | - | - |
Long Term Debt Current |
1.37 M | 1.59 M | 1.57 M | 1.25 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 73 M | 48.2 M | 52.7 M | - | - | - | - | - | - | - |
Total Current Liabilities |
4.25 M | 5.45 M | 5.64 M | 9.07 M | 4.89 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.31 M | 6.98 M | 9.48 M | 15 M | 6.71 M | 77.9 M | 69.9 M | 55.3 M | - | - | - | - | - | - | - |
Retained Earnings |
-283 M | -262 M | -232 M | -198 M | -149 M | -112 M | -92.3 M | -75.6 M | - | - | - | - | - | - | - |
Total Assets |
22.9 M | 45.4 M | 74.4 M | 118 M | 153 M | 21.4 M | 1.22 M | 1.85 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
8.67 M | 9.99 M | 13 M | 17.8 M | 7.16 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
18.6 M | 38.4 M | 64.9 M | 103 M | 147 M | -56.4 M | -68.7 M | -53.5 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
18.6 M | 38.4 M | 64.9 M | 103 M | 147 M | -56.4 M | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Sensei Biotherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 4 K | 35 K | 98 K | 206 K | 377 K | 571 K | 768 K | 962 K | 1.16 M | 1.35 M | 1.58 M | 1.68 M | 1.72 M | 1.85 M | 1.67 M | - | 567 K | 567 K | 567 K | 567 K | 567 K | 567 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
9.58 M | 14.2 M | 4.58 M | 4.47 M | 6.29 M | 6.98 M | 7.48 M | 7.61 M | 8.22 M | 9.48 M | 10.7 M | 10.4 M | 13.1 M | 15 M | 14.8 M | 12.1 M | 14.7 M | 6.71 M | 6.04 M | 4.6 M | 3.22 M | 5.54 M | 5.54 M | 5.54 M | 5.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-469 M | -453 M | -278 M | -274 M | -269 M | -262 M | -254 M | -247 M | -240 M | -232 M | -224 M | -217 M | -208 M | -198 M | -186 M | -172 M | -162 M | -149 M | -140 M | -130 M | -120 M | -112 M | -112 M | -112 M | -112 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
189 M | 205 M | 27.6 M | 31.8 M | 38.3 M | 45.4 M | 53.3 M | 59.8 M | 66.7 M | 74.4 M | 81.7 M | 89.6 M | 108 M | 118 M | 129 M | 138 M | 150 M | 153 M | 161 M | 168 M | 174 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
26.9 M | 152 M | 10.6 M | 12.6 M | 9.88 M | 9.99 M | 19.1 M | 11.9 M | 11 M | 13 M | 11.3 M | 10.2 M | 8.11 M | 17.8 M | 11.4 M | 9.9 M | 8.72 M | 7.16 M | 9.53 M | 15.6 M | 169 M | 16.6 M | 16.6 M | 16.6 M | 16.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
180 M | 191 M | 23 M | 27.3 M | 32 M | 38.4 M | 45.8 M | 52.2 M | 58.5 M | 64.9 M | 71 M | 79.2 M | 94.8 M | 103 M | 114 M | 126 M | 135 M | 147 M | 155 M | 163 M | 171 M | 15.9 M | 15.9 M | 15.9 M | 15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
173 M | -137 M | 23 M | 27.3 M | 32 M | 38.4 M | 45.8 M | 52.2 M | 58.5 M | 64.9 M | 71 M | 79.2 M | 94.8 M | 103 M | 114 M | 126 M | 135 M | 147 M | 155 M | 163 M | 171 M | -56.4 M | -56.4 M | -56.4 M | -56.4 M | -68.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sensei Biotherapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Biotechnology
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 210.23 | 2.28 % | $ 12.8 B |  Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.87 | 0.05 % | $ 5.21 M |  USA |
 |
Kymera Therapeutics
KYMR
|
$ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 22.12 | 1.26 % | $ 2.38 B | USA |
 |
Larimar Therapeutics
LRMR
|
$ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
$ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
$ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 21.3 | 4.46 % | $ 1.02 T |  France |
 |
Syndax Pharmaceuticals
SNDX
|
$ 12.9 | 0.89 % | $ 1.12 B | USA |
 |
Soligenix
SNGX
|
$ 0.35 | 1.67 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.42 | 0.71 % | $ 1.24 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.45 | 1.6 % | $ 1.52 B | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 17.1 | 0.03 % | $ 1.71 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.69 | 0.6 % | $ 2.21 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.48 | 0.2 % | $ 5.91 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 9.98 | 4.02 % | $ 1.09 B | USA |
|
Protara Therapeutics
TARA
|
$ 2.32 | 1.46 % | $ 99.4 M | USA |
 |
Relay Therapeutics
RLAY
|
$ 16.28 | 1.41 % | $ 2.79 B | USA |
 |
Pfizer
PFE
|
$ 29.58 | 0.54 % | $ 168 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
$ 37.88 | 0.5 % | $ 2.14 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.67 | 1.08 % | $ 31.1 B |  Japan |
 |
Revolution Medicines
RVMD
|
$ 177.96 | 0.22 % | $ 33.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 86.17 | 0.6 % | $ 5.6 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.26 | 0.9 % | $ 251 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.27 | 6.22 % | $ 575 M | USA |
 |
Pulmatrix
PULM
|
$ 1.36 | 4.61 % | $ 4.97 B | USA |
 |
Zoetis
ZTS
|
$ 79.38 | 1.22 % | $ 35.2 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.54 | 1.81 % | $ 1.43 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.96 | 2.62 % | $ 1.32 B | Israel |
 |
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | USA |
 |
Zymeworks
ZYME
|
$ 25.03 | 0.16 % | $ 1.29 B |  Canada |
 |
AC Immune SA
ACIU
|
$ 2.39 | 2.08 % | $ 241 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
$ 2.06 | 4.8 % | $ 122 M |  China |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.49 | 11.15 % | $ 2.33 M | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.4 | 0.34 % | $ 178 M | Schweiz |
 |
ADMA Biologics
ADMA
|
$ 10.68 | 3.77 % | $ 2.55 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 20.09 | 0.19 % | $ 225 M | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.31 | 3.08 % | $ 289 M | USA |
 |
Amgen
AMGN
|
$ 432.49 | 0.08 % | $ 233 B | USA |
 |
Ardelyx
ARDX
|
$ 3.09 | 2.51 % | $ 745 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 3.37 | 9.06 % | $ 122 M | USA |